Advances in Lymphoma.

Slides:

Advertisements

Similar presentations

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma

Advertisements

There are many ways to slice the “lymphoma pie”. Simplified classification of NHLs Indolent (low grade) Aggressive (intermediate grade) Highly aggressive.

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Kinase Inhibitors in B-cell Lymphomas: What Does the Future Hold?

What’s New in Indolent NHL, MCL and PTCL

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

2013 Lymphoma Update Outline Follicular lymphoma Hodgkin’s lymphoma Chronic lymphocytic leukemia.

Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.

Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot.

Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL? Bertrand Coiffier Service d’Hématologie Hospices Civils de Lyon.

Lymphoma overview and current therapies John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean.

Reeder CB et al. ASCO 2009; Abstract (Poster)

Lymphoma NICE guidelines July 2016

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy - DOI: /

Fujiwara H et al. Proc ASH 2015;Abstract 181.

Aggressive NHL and Hodgkin Lymphoma

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Updates in Hodgkin Lymphoma

Hot Topics in Lymphoma Supportive Care

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Peripheral T-Cell Lymphoma in 2013

Prolonging Progression-Free Survival in Follicular Lymphoma

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Disclosures Geisler: Advisory boards and IDMC’s:

Goals of Therapy in Relapsed CLL

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Activity Goals. Activity Goals Case Presentation.

Jonathan W. Friedberg M.D., M.M.Sc.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Focus on lymphomas Cancer Cell

Updates in Lymphoma From Recent Congresses

Jonathan W. Friedberg M.D., M.M.Sc.

Ansell SM et al. Proc ASH 2012;Abstract 798.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Recent Advances in the Treatment of Lymphoma

Advances in Multiple Myeloma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

How to Select Therapy In Newly Diagnosed CLL

Made by: reham Talal Khalil Asmaa Mohamed alghefari

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Approaches in Newly Diagnosed Multiple Myeloma: When and What

Non-Chemotherapy Combinations in CLL

Presented By Steven Park at 2016 ASCO Annual Meeting

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Practical Guidance on the Management of Pan-Negative NSCLC

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

First-Line FCR: Effect of del(17p) on PFS and OS

Tailoring Therapy in the Newly Diagnosed Patient With CLL

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

An algorithmic approach to FL

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Treatment Initiation and Selection in Newly Diagnosed CLL

Presentation transcript:

Advances in Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ibrutinib Monotherapy

GS-9973 and Idelasib in Patients With R/R CLL

ABT-199 in Patients With R/R CLL/SLL

Hodgkin Lymphoma

ABVD With and Without Bleomycin and/or Dacarbazine

Brentuximab Vedotin Followed by ABVD in Patients With Untreated NHL

Single-Agent Brentuximab Vedotin in R/R Hodgkin Lymphoma

Follicular Lymphoma

Prognostic Value of PET-CT After FL Therapy in FL

FOLL05, 5-Year Follow-up

Alliance/CALGB 50803 Lenalidomide Plus Rituximab for Untreated FL

ROMULUS Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients With R/R FL

Diffuse Large B-Cell Lymphoma

Two Different R-CHOP Variants

ABT-199 for DLBCL

Monitoring MRD Using Cellular and Acellular Blood DNA

Mantle Cell Lymphoma

R-CHOP vs VR-CAP for BMT-Ineligible Newly Diagnosed Patients With MCL

Subcutaneous Bortezomib in Relapsed MCL

Safety of Ibrutinib in R/R MCL

T-Cell Lymphoma

Alisertib for PTCL

Response to Romidepsin by Number of Lines of Prior Therapies in R/R PTCL

Topical SHP-141 for CTCL

Outcomes of Patients With PTCL From the BCCA Registry After Standard Chemotherapy

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)